However, the authors also point out that a reduced number of primordial follicles in young girls with cancer could be another explanation. To me this seems to be the most biologically plausible explanation. The authors correctly point out that the lower serum levels of AMH in these girls may be due to reduced AMH production by individual follicles as a result of follicle dysfunction related to the chronic disease. The seminal point is other factors may well influence serum AMH levels besides the number of pre-antral follicles in the ovary. The investigators show that AMH levels correlate with impairment of these surrogate markers of general health status in girls. The seminal finding is that, in young girls with cancer, serum anti-Müllerian hormone (AMH) levels correlate significantly with temperature, C-reactive protein and hemoglobin. They compare the findings with a control group of 250 age-matched healthy girls. In a cross-sectional study the authors examine serum AMH levels in 208 girls with newly diagnosed cancer who are attending a cancer center. I also applaud the authors for employing scientifically accurate terminology in their report. I congratulate the authors for testing hypotheses that challenge current dogma. The findings in this publication force us to reconsider this long-held view.

Current dogma attributes to this marker the ability to determine the number of primordial follicles remaining in the ovary. (2013) provide us with seminal evidence about a serum marker that purportedly informs us about current and future ovarian function.

In the current issue of Human Reproduction van Dorp et al.

Lady from flat earth society